.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

In-person and virtual events just for HCPs

SpecialtySee All >

Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer

Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

Emergence of Biosimilars in Oncology

EP. 1: An Overview of Biosimilarity

March 16th 2020

EP. 2: The Adoption and Choice of Biosimilars

March 16th 2020

EP. 3: Decision Makers for Formulary Approval of Biosimilars

March 16th 2020

EP. 4: Biosimilar Use in the Treatment of NSCLC

March 16th 2020

EP. 5: The Use of Biosimilars in HER2+ Breast Cancer

March 16th 2020

EP. 6: The Complexity of Choosing Biosimilars in Oncology

March 16th 2020

EP. 7: Evidence-Based Extrapolation for Biosimilars

March 16th 2020

EP. 8: Biosimilar Interchangeability in Practice

March 16th 2020

EP. 9: Pharmacovigilance Requirements for Biosimilar Products

March 16th 2020

EP. 10: Educating Physicians When Prescribing Biosimilars

March 16th 2020

EP. 11: The Availability of Multiple Biosimilars for 1 Biologic

March 16th 2020

EP. 12: The Future Direction of Biosimilars

March 16th 2020